Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer
Geniver El Tekle,
Laura P. Brandt,
Giuseppina M. Carbone,
Steven A Carr,
Marianna Kruithof-de Julio,
Mark A. Rubin,
Namrata D Udeshi,
Jean-Philippe P. Theurillat
Posted 08 Jul 2020
bioRxiv DOI: 10.1101/2020.07.08.193581 (published DOI: 10.1038/s41467-020-20820-x)
Posted 08 Jul 2020
Driver genes with a mutually exclusive mutation pattern across tumor genomes are thought to have overlapping roles in tumorigenesis. In contrast, we show here that mutually-exclusive prostate cancer driver alterations involving the ERG transcription factor and the ubiquitin ligase adaptor SPOP are synthetic sick. At the molecular level, the incompatible cancer pathways are driven by opposing functions in SPOP. ERG up-regulates wild type SPOP to dampen androgen receptor (AR) signaling and sustain ERG activity through degradation of the bromodomain histone reader ZMYND11. Conversely, SPOP-mutant tumors stabilize ZMYND11 to repress ERG-function and enable oncogenic androgen receptor signaling. This dichotomy regulates the response to therapeutic interventions in the AR pathway. While mutant SPOP renders tumor cells susceptible to androgen deprivation therapies, ERG promotes sensitivity to high-dose androgen therapy and pharmacological inhibition of wild type SPOP. More generally, these results define a distinct class of antagonistic cancer drivers and a blueprint toward their therapeutic exploitation. ### Competing Interest Statement MAR is listed as a co-inventor on US and International patents in the diagnostic and 385 therapeutic fields of ETS gene fusion prostate cancers (Harvard and University of 386 Michigan) and SPOP mutations (Weill Cornell Medicine). JPT has received funding for 387 the venue of scientific conferences from Astellas, MSD, and Janssen/Cilag. The remaining 388 authors declare no competing financial interests. Correspondence and requests for 389 materials should be addressed to J.P.T. (JeanP_Theurillat@ior.iosi.ch)
- Downloaded 404 times
- Download rankings, all-time:
- Site-wide: 82,561
- In cancer biology: 2,423
- Year to date:
- Site-wide: 77,806
- Since beginning of last month:
- Site-wide: 78,751
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!